Announced that World Health Organization (WHO) has approved “icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States ...

The company's lead asset, BMF-219, a covalent menin inhibitor targeting diabetes, has been the subject of intense scrutiny following a clinical hold earlier this year. This comprehensive analysis ...

The company's lead asset, BMF-219, a covalent menin inhibitor targeting diabetes, has been the subject of intense scrutiny following a clinical hold earlier this year. This comprehensive analysis ...

that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 ...

Biomea Fusion, Inc.: Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small ...

Despite this amount being acknowledged as a limited runway, the recent lifting of the clinical hold on icovamenib, formerly known as BMF-219, and the anticipation of randomized trial data have led to ...

Revenue of $556.9 million, a 6.4% increase Gross profit increased 7.7% to $161.8 million, with gross profit margin of 29.1%, a 40 basis point expansion Net income of $13.8 million and Earnings Per ...

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea” or "the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and ...

The partnership will leverage Neomorph’s molecular glue discovery platform. Credit: PeopleImages.com – Yuri A/Shutterstock. Biogen and Neomorph have entered a research partnership aimed at discovering ...

Announced that World Health Organization (WHO) has approved "icovamenib" as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted ...